Institutional members access full text with Ovid®

Dextroamphetamine for Cocaine-Dependence Treatment: A Double-Blind Randomized Clinical Trial

Grabowski, John PhD; Rhoades, Howard PhD; Schmitz, Joy PhD; Stotts, Angela PhD; Daruzska, Lee Ann RPh; Creson, Dan MD, PhD; Moeller, F. Gerard MD

Journal of Clinical Psychopharmacology: October 2001 - Volume 21 - Issue 5 - pp 522-526
Brief Reports

A properly implemented agonist treatment regimen should improve retention and reduce illicit drug use. Cocaine-dependent subjects (N = 128) were enrolled in a 12-week randomized, double-blind, placebo-controlled trial. In the multistage dosing design, subjects initially received placebo (PBO) or 15 to 30 mg of dextroamphetamine sulfate, sustained-release capsules. At week 5, the dose doubled to 30 mg or 60 mg for active groups. Subjects attended the clinic twice a week, provided urine samples, obtained medication, and had one behavioral therapy session a week. Retention was best for the 15-to 30-mg group, whereas the proportion of benzoylecgonine-positive urine screens was, from lowest to highest, 30 to 60 mg, 15 to 30 mg, and PBO at study end. Dosing must be refined. The results provide support for additional examination of the agonist model in psychostimulantdependence treatment.

Substance Abuse–Medications Development Research Center, Department of Psychiatry and Behavioral Sciences, School of Medicine, University of Texas–Houston, Houston, Texas

Received August 20, 1999; accepted after revision September 11, 2000.

Address requests for reprints to: John Grabowski, PhD, SARC, Department of Psychiatry and Behavioral Sciences, Health Science Center, University of Texas-Houston, 1300 Moursund, Houston, Texas 77005. Address e-mail to: john.grabowski@uth.tmc.edu.

© 2001 Lippincott Williams & Wilkins, Inc.